XTX Markets’s Myriad Genetics MYGN Stock Holding History

XTX Markets’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,807	Closed	-$168K	–	162
2020 Q2	$168K	Buy	+14,807	New	+$210K	0.57%	97

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

XTX Markets's MYGN Position: Q3 2020 in Review

XTX Markets sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 14,807 shares — an estimated $168K sold.

XTX Markets first reported a position in MYGN in Q2 2020 and held it in 1 quarter. The position peaked at $168K in Q2 2020. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

XTX Markets reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
XTX Markets sold 14,807 Myriad Genetics shares in Q3 2020, an estimated $168K.
XTX Markets first reported a position in Myriad Genetics in Q2 2020 and held it in 1 quarter.
XTX Markets's Myriad Genetics position peaked at $168K in Q2 2020.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on XTX Markets's 13F filing for Q3 2020, filed 29 Oct 2020.